MicroRNA-208a is a cardiac specific oligo-nucleotide. We aimed at investigating the ability of microRNA-208a to diagnose myocardial infarction and predict the outcome of primary percutaneuos coronary angiography (PCI). Patients (n = 75) presented by chest pain were recruited into two groups. Group 1 (n = 40) had ST elevation myocardial infarction (STEMI) and underwent primary PCI: 21 patients had sufficient reperfusion and 19 had no-reflow. Group 2 (n = 35) had negative cardiac troponins (cTns). Plasma microRNA-208a expression was assessed using quantitative polymerase chain reaction and patients were followed for occurrence of in-hospital major adverse cardiac events (MACE). MicroRNA-208a could diagnose of MI (AUC of 0.926). After primary PCI, it was superior to cTnT in prediction of no-reflow (AUC difference of 0.231, P = 0.0233) and MACE (AUC difference of 0.367, P = 0.0053). Accordingly, circulating levels of miR-208a can be used as a diagnostic marker of MI and a predictor of no-reflow and in-hospital MACE.

Receiver operating curve analysis of no-reflow prediction of miRNA208a, CK-MB and hs-Troponin T. MicroRNA-208a shows significantly higher prediction of no-reflow as compared to routine cardiac biomarkers.

MicroRNA-208a是心脏特异的寡核苷酸。我们旨在研究microRNA-208a诊断心肌梗塞并预测原发性经皮冠状动脉造影（PCI）结果的能力。 出现胸痛的患者（n = 75）被分为两组。第1组（n  = 40）患有ST抬高型心肌梗塞（STEMI）并接受了原发性PCI：21例患者有足够的再灌注，19例没有再流。第2组（ñ = 35）的心脏肌钙蛋白（cTns）为阴性。使用定量聚合酶链反应评估血浆microRNA-208a的表达，并跟踪患者院内主要不良心脏事件（MACE）的发生情况。MicroRNA-208a可以诊断MI（AUC为0.926）。初次PCI后，在无复流（AUC差异为0.231，P  = 0.0233）和MACE（AUC差异为0.367，P  = 0.0053）的预测方面优于cTnT 。因此，miR-208a的循环水平可以用作MI的诊断指标以及无复流和院内MACE的预测指标。

miRNA208a，CK-MB和hs-肌钙蛋白T的无复流预测的受体工作曲线分析。与常规的心脏生物标志物相比，MicroRNA-208a的无复流预测显着更高。